NOVEL STRATEGIES TO COMBAT ANTIBIOTIC-RESISTANT INFECTIONS
Keywords:
antibiotic resistance, antimicrobial therapy, bacteriophage, novel antibiotics, antimicrobial peptides, nanotechnology, microbiome modulation, combination therapy, drug delivery systems, public health.Abstract
Antibiotic resistance has become a global public health challenge, limiting the effectiveness of conventional treatments and increasing morbidity and mortality rates. This article reviews novel strategies to combat antibiotic-resistant infections, including the development of new antibiotics, bacteriophage therapy, antimicrobial peptides, and the use of nanotechnology-based drug delivery systems. Additionally, it explores alternative approaches such as microbiome modulation, immunotherapy, and combination therapies to enhance the efficacy of existing antibiotics. The study emphasizes the importance of integrating innovative therapeutic methods with proper antibiotic stewardship to effectively manage resistant infections and reduce the risk of their spread.
Downloads
References
Ventola, C. L. (2015). The antibiotic resistance crisis: part 1: causes and threats. P & T, 40(4), 277–283.
World Health Organization (WHO). (2020). Antimicrobial resistance. Retrieved from https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
Davies, J., & Davies, D. (2010). Origins and evolution of antibiotic resistance. Microbiology and Molecular Biology Reviews, 74(3), 417–433.
Bassetti, M., Peghin, M., & Vena, A. (2019). Treatment of infections due to multidrug-resistant Gram-negative bacteria. Frontiers in Medicine, 6, 74.
Lin, D. M., Koskella, B., & Lin, H. C. (2017). Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World Journal of Gastrointestinal Pharmacology and Therapeutics, 8(3), 162–173.
Hancock, R. E., & Sahl, H. G. (2006). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nature Biotechnology, 24(12), 1551–1557.
Ventola, C. L. (2015). The antibiotic resistance crisis: part 2: management strategies and new agents. P & T, 40(5), 344–352.
Laxminarayan, R., et al. (2013). Antibiotic resistance—the need for global solutions. The Lancet Infectious Diseases, 13(12), 1057–1098.
Spellberg, B., et al. (2013). Combating antimicrobial resistance: policy recommendations to save lives. Clinical Infectious Diseases, 56(9), 1267–1278.
Tharmalingam, N., et al. (2019). Nanotechnology-based antimicrobial strategies for combating drug-resistant bacteria. International Journal of Molecular Sciences, 20(22), 5586.
Tacconelli, E., et al. (2018). Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria. The Lancet Infectious Diseases, 18(3), 318–327.
O’Neill, J. (2016). Tackling drug-resistant infections globally: final report and recommendations. Review on Antimicrobial Resistance.
Giacometti, A., et al. (2015). Combination therapy for multidrug-resistant bacterial infections: a review of in vitro and in vivo studies. Journal of Antimicrobial Chemotherapy, 70(8), 2130–2143.
Fischbach, M. A., & Walsh, C. T. (2009). Antibiotics for emerging pathogens. Science, 325(5944), 1089–1093.
Reardon, S. (2014). Phage therapy gets revitalized. Nature, 510, 15–16.
